Nepsis Inc. Increases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Nepsis Inc. grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,921 shares of the biotechnology company’s stock after buying an additional 3,113 shares during the period. United Therapeutics accounts for approximately 2.8% of Nepsis Inc.’s portfolio, making the stock its 10th largest holding. Nepsis Inc. owned approximately 0.12% of United Therapeutics worth $19,378,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Impact Partnership Wealth LLC boosted its position in United Therapeutics by 37.4% in the fourth quarter. Impact Partnership Wealth LLC now owns 974 shares of the biotechnology company’s stock worth $344,000 after purchasing an additional 265 shares during the last quarter. FCG Investment Co lifted its position in shares of United Therapeutics by 10.3% during the 4th quarter. FCG Investment Co now owns 5,040 shares of the biotechnology company’s stock valued at $1,778,000 after buying an additional 472 shares in the last quarter. Veracity Capital LLC raised its stake in United Therapeutics by 134.3% during the 4th quarter. Veracity Capital LLC now owns 2,523 shares of the biotechnology company’s stock valued at $890,000 after purchasing an additional 1,446 shares during the period. Galvin Gaustad & Stein LLC raised its stake in United Therapeutics by 6.0% during the 4th quarter. Galvin Gaustad & Stein LLC now owns 26,512 shares of the biotechnology company’s stock valued at $9,354,000 after purchasing an additional 1,505 shares during the period. Finally, Inspire Investing LLC raised its stake in United Therapeutics by 18.2% during the 4th quarter. Inspire Investing LLC now owns 8,351 shares of the biotechnology company’s stock valued at $2,946,000 after purchasing an additional 1,286 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $370.83 on Friday. The company has a market capitalization of $16.56 billion, a price-to-earnings ratio of 16.29, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The stock has a 50-day simple moving average of $365.19 and a 200 day simple moving average of $355.61.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the previous year, the company posted $5.38 earnings per share. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. On average, equities research analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on UTHR shares. Argus lifted their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. HC Wainwright boosted their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. TD Cowen boosted their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, Oppenheimer increased their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $378.36.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 7,800 shares of the business’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the completion of the transaction, the chief financial officer now owns 6,978 shares of the company’s stock, valued at $2,442,300. The trade was a 52.78 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $940,373.07. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 146,848 shares of company stock worth $55,165,099. 11.90% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.